Background Neoadjuvant chemotherapy improves outcome in osteosarcoma. Determination
of optimum regimens for survival, toxicity and prognostic factors requires randomised …

BACKGROUND The evaluation variables influencing systemic and local recurrence and
final outcome are extremely important in defining risk‐adapted treatments for patients with …

PURPOSE: To define prognostic factors for response and long-term outcome for a wide
spectrum of osteosarcomas, extending well beyond those of the typical young patient with …

Objective To determine the effectiveness of radiation therapy for local control of
nonmetastatic osteosarcoma of the extremities after induction chemotherapy. Patients and …

Background To identify predictive factors of disease-free survival (DFS) in patients with non-
metastatic osteosarcoma of the extremity, treated with primary chemotherapy and delayed …

BACKGROUND Risk factors for local recurrence (LR) after osteosarcoma, such as surgical
margins and histologic response to preoperative treatment, have been well documented …

Background Chemotherapy in the multimodality treatment of osteosarcoma has improved
survival. Reported outcomes on adult patients are limited. Poor necrosis rates post …

BACKGROUND: The authors present the long‐term follow‐up (> 25 years) data from 1 of the
original prospective, randomized trials that compared adjuvant chemotherapy with expectant …

Background: Effective adjuvant or neoadjuvant regimens of chemotherapy have dramatically
improved the prognosis of patients with high-grade osteosarcoma of the extremity, localized …

Over the past 30 years, treatment advances and the addition of neoadjuvant chemotherapy
have led to improved 5-year survival in patients with osteosarcoma. More recent literature …